Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Katie Niland"'
Autor:
Robert H.I. Andtbacka, Yan Wang, Robert H. Pierce, Jean S. Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, Katie Niland, Robert D. Arbeit, Sudha Parasuraman, Kris Bickley, Cecilia CS Yeung, Lauri D. Aicher, Kimberly S. Smythe, Lu Gan
Publikováno v:
Cancer Research Communications. 2:904-913
Purpose: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Antibody panels used for mIF analyses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2a1af716f0bd76c6e9fa7b043dbd23
https://doi.org/10.1158/2767-9764.22545773.v1
https://doi.org/10.1158/2767-9764.22545773.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Serum cytokine and chemokine changes at the end of the 3-week monotherapy period compared to baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5098d1822b7b01f14f78eb4c3a72ba
https://doi.org/10.1158/2767-9764.22545770.v1
https://doi.org/10.1158/2767-9764.22545770.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Purpose:Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412d1a88bdb6c622134f34d6dd3e332d
https://doi.org/10.1158/2767-9764.c.6551033.v1
https://doi.org/10.1158/2767-9764.c.6551033.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Shared TCR TIL sequences taken from tumor biopsy of patient #5 at various timepoints.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a79627298ef8dc5b78551cef478a86
https://doi.org/10.1158/2767-9764.22545779.v1
https://doi.org/10.1158/2767-9764.22545779.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Depiction of T cell clone mobilization from peripheral blood to melanoma site on day 1 and at EOT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e18f10426dc9934d3fce1d6e4d95278
https://doi.org/10.1158/2767-9764.22545776
https://doi.org/10.1158/2767-9764.22545776
Autor:
Robert Arbeit, Lu Gan, David F. McDermott, Yan Wang, Katie Niland, Tracy L. Rose, Sudha Parasuraman, Toni K. Choueiri, Yawen Ju, Michael B. Atkins, Robert S. Alter
Publikováno v:
Investigational New Drugs. 39:1019-1027
Background The CXCR4 chemokine receptor promotes tumor survival through mechanisms that include suppressing antitumor immune responses. Mavorixafor (X4P-001) is an oral, selective, allosteric CXCR4 inhibitor that decreases the recruitment of immunosu
Autor:
Toni K, Choueiri, Michael B, Atkins, Tracy L, Rose, Robert S, Alter, Yawen, Ju, Katie, Niland, Yan, Wang, Robert, Arbeit, Sudha, Parasuraman, Lu, Gan, David F, McDermott
Publikováno v:
Investigational new drugs. 39(4)
Background The CXCR4 chemokine receptor promotes tumor survival through mechanisms that include suppressing antitumor immune responses. Mavorixafor (X4P-001) is an oral, selective, allosteric CXCR4 inhibitor that decreases the recruitment of immunosu
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics
What is known and objective Ponatinib is a potent oral tyrosine kinase inhibitor with activity against BCR-ABL, the primary driver of chronic myeloid leukaemia and Philadelphia chromosome–positive acute lymphoblastic leukaemia. This single-centre,
Autor:
Eleni Tsiroyanni, Merrick I. Ross, Yan Wang, Robert H. Pierce, Lu Gan, Melinda L. Yushak, Kenneth F. Grossmann, Robert H.I. Andtbacka, Katie Niland, Mohammed M. Milhem, Sudha Parasuraman, Jean S. Campbell, Kam Sprott
Publikováno v:
Cancer Research. 78:613-613
Background: The CXCR4/CXCL12 pathway plays a central role in the trafficking of key immune cells in the tumor microenvironment (TME). X4P-001 is an oral, selective, allosteric CXCR4 inhibitor. We hypothesize that the disruption of CXCR4/CXCL12 signal